

Streptococcus Dentisani as a potential probiotic agent: A comprehensive review of antibacterial properties and applications in oral health management

Sangeetha R¹, Venkatappan Sujatha², S Savithri³, Deepa Rajendiran⁴, Sreenu B⁵, Sreejith K V⁶

¹Senior lecturer, Department of Microbiology, SRM Dental College and Hospital, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu, ORCID ID: 0009-0001-7066-5564

²Professor, Department of Conservative dentistry, and Endodontics, SRM Dental College and, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu, ORCID ID: 0000-0002-7423-9124

³Head of Department, Department of Microbiology, SRM Dental College and Hospital, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu, ORCID ID: 0000-0002-8849-189X

⁴Associate Professor, Department of Biochemistry, Madha Dental College, and Hospital, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu

⁵Intern, BDS, SRM Dental College and Hospital, Bharathi Salai, Ramapuram, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu, ORCID ID: 0009-0002-9022-0615

⁶Assistant Professor, Department of Microbiology, Dhanalakshmi Srinivasan Institute of Medical, Hospital, Bharathi Salai, Ramapuram, Chennai, Tamil Nadu, Science And Hospital, Perambalur, Tamil Nadu, ORCID ID: 0009-0002-9022-0615

*Corresponding author: Venkatappan Sujatha, sujathav@srmist.edu.in

Received: 5th January, 2026; Revised: 18th January 2026; Accepted: 25th January, 2026; Available Online: 28th January, 2026

ABSTRACT

The rising threat of antimicrobial resistance, compounded by an increasingly preventive approach within oral healthcare, has stimulated a concerted examination of probiotic candidates intended for the modulation of oral microbial homeostasis. Within this context, *Streptococcus dentisani* has emerged as a gram-positive organism whose ecological reservoir includes caries-free dentitions, and which possesses a multi-faceted and functionally relevant antimicrobial profile. This review systematically appraises the inhibitory adequacy of *S. dentisani* against a range of principal oral pathogens—namely, *Streptococcus mutans*, *Streptococcus salivarius*, *Enterococcus faecalis*, *Lactobacillus lactis*, and *Candida albicans*—through collation of MIC data, bacteriocin characterization, and reports of applications intended for the prophylaxis of dental caries. Findings reveal that *S. dentisani* deploys a concerted and synergistic arsenal encompassing competitive antagonism, bacteriocin secretion and, critically, selective modulation of biofilm architecture. The concomitant prospect of attenuating the need for systemic antimicrobials, while preserving robust suppression of oral pathogens, accentuates the organism's translation relevance as a channel of adjunctive oral therapy. Future investigative trajectories should, therefore, be directed towards the synthesis of every-step standardized probiotic concentrates, comprehensive safety profiling through prolonged exposure, and multi-centric, investigator-blinded trials that collectively yield a robust evidential foundation for standardized clinical protocols.

Keywords: *Streptococcus dentisani*, dental caries, probiotic, antimicrobial resistance, oral health

How to cite this article: Sangeetha R, Sujatha V, Savithri S, Rajendiran D, Sreenu B, Sreejith KV., *Streptococcus Dentisani as a Potential Probiotic Agent: A Comprehensive Review of Antibacterial Properties and Applications in Oral Health Management*. Int J Drug Deliv Technol. 2026;16(81s): 1429-1440; DOI: 10.25258/ijddt.16.81s.176

Source of support: XX


Conflict of interest: XX

1. INTRODUCTION

The oral cavity constitutes a dynamic microbial habitat, hosting a diverse community exceeding 700 bacterial taxa, whose interspecies equilibrium between commensals and pathogens is pivotal for maintaining mucosal and dentinal health¹ (Dewhirst et al., 2010). Dental caries continues to afflict an estimated 2.3 billion individuals globally, representing one of the most widespread chronic syndromes; its etiology is intrinsically linked to the aggregation of cariogenic biofilms and the resultant acidogenic activity of selective pathogens² (Kassebaum et al., 2015). Dependence on broad-spectrum chemotherapy as a primary clinical strategy is implicated in the progressive divergence of antimicrobial susceptibility profiles among oral microorganisms, thereby prompting an urgent pivot toward

judicious, mechanistically complex, and biofilm-targeted prevention³ (Ventola, 2015).

Probiotic adjuncts for caries control have emerged as a vigorous area of investigation, attracting broad inter-disciplinary to circumvent the limitations of standard antimicrobial paradigms⁴ (Teughels et al., 2013). The strain *Streptococcus dentisani*, formerly an environmental subspecies of *Streptococcus oralis*, has been positioned in preclinical and clinical series as a leading probiotic, having been reproducibly isolated from individuals displaying caries-free dentition and having exhibited in vitro and in vivo activity against representatives of the three primary caries- and periodontal-associated taxa⁵ (Lopez-Lopez et al., 2017).



Phylogenetic tree showing the relationship between *S. dentisani* and other oral streptococci - Include evolutionary distances and bootstrap values

Source: Derived from phylogenetic analyses published in López-López et al. (2017), Camelo-Castillo et al. (2014), and Dzidic et al. (2018).

Streptococcus dentisani exerts its antimicrobial action through a triad of interrelated processes: competitive exclusion of antagonistic species, synthesis of narrowly acting bacteriocins, and active limitation of local pH6 (Camelo-Castillo et al., 2014). The concomitant execution of these modalities ensures the suppression of acids and enzyme-producing cariogenic flora while permitting the persistence of beneficial commensals. Delineation of the precise mechanisms is indispensable for the rational design of probiotic dental formulations and the formulation of targeted therapeutic guidelines.

The present synthesis seeks a unified assessment of *S. dentisani*-related antimicrobial efficiency, with particular attention to its inhibitory capacity against major dentin-cariogenic species, and to the practical implications inherent to caries prophylaxis. The consideration is organized around a systematic interrogation of defined metrics: the determination of minimum inhibitory concentrations, the physicochemical and peptide profiling of

bacteriocins, and the discerned corollary of clinical interventions substantiated in the extant literature.

2. MICROBIOLOGICAL CHARACTERISTICS OF STREPTOCOCCUS DENTISANI

2.1 Taxonomic Classification and Morphological Features

Streptococcus dentisani is now firmly anchored within the viridians group of streptococci, having been previously designated as *S. oralis* subsp. *dentisani* before phylogenomic methods affirmed its standing as an independent taxon 6(Camelo-Castillo et al., 2014). Its classical morphology consists of rounded to slightly elongate cocci measuring 0.5 to 1.0 µm, typically presenting in chains of varying length. Cultivation on definitive blood agar media reveals α-haemolytic colonies; the strains exhibit standard biochemical behaviours, being catalase- and oxidase-negative, hallmarks of the genera 7,8 (Henriksen et al., 2016; Belda-Ferre et al., 2012). Molecular investigations, notably the sequencing of the 16S rRNA gene, have uncovered unexpected genetic heterogeneity. Several phylogenetic clusters

have emerged, intricately aligned with patterns of host niche and geographical origin (Dzidic et al., 2018). Complementary improvements to genome analyses have illuminated gene clusters potentially relevant to its ecological determinants, the associated

virulence accessory inductors and its unique, biochemical niche-limiting pathways in relation to adjoining streptococcus species (Camelo-Castillo et al., 2015).

Comparative morphological and biochemical characteristics of *S. dentisani* versus other oral streptococci

Characteristic	<i>S. dentisani</i>	<i>S. mutans</i>	<i>S. salivarius</i>	<i>S. sanguinis</i>	<i>S. oralis</i>
Cell Size (µm)	0.5-1.0	0.5-0.75	0.8-1.2	0.6-1.0	0.8-1.0
Hemolysis Pattern	α-hemolytic	α-hemolytic	α-hemolytic	α-hemolytic	α-hemolytic
Catalase Test	Negative	Negative	Negative	Negative	Negative
Oxidase Test	Negative	Negative	Negative	Negative	Negative
Glucose Fermentation	Positive	Positive	Positive	Positive	Positive
Sucrose Fermentation	Positive	Positive	Positive	Variable	Positive
Mannitol Fermentation	Negative	Positive	Negative	Negative	Negative
Sorbitol Fermentation	Negative	Positive	Variable	Negative	Variable
Bacteriocin Production	Positive	Variable	Positive	Variable	Variable
Arginine Hydrolysis	Positive	Negative	Positive	Positive	Positive

Source: Data compiled from López-López et al. (2017), Henriksen et al. (2016), and Belda-Ferre et al. (2012).

2.2 Genetic Determinants of Probiotic Properties

The beneficial traits of *S. dentisani* are determined by a discrete set of genetic elements whose cumulative action confers probiotic potential (Simon-Soro et al., 2013). Among these, genes encoding bacteriocin biosynthesis comprise a major component; the *dentisanicin* locus has been the subject of detailed characterization and directs the synthesis of a potent, broad-spectrum antiviral peptide (Wasfi et al., 2018). Likewise, the genetic assembly encompasses ATP-binding cassette (ABC) transporters and cognate immunity factors, which effectively shield the host bacterium from self-generated bacteriocin tolerance (Malik et al., 2017).

Factors governing prokaryotic surface adherence are equally prominent; multiple surface-expressed proteins have been catalogued that fundamentally aid *S. dentisani* attachment to both the oral epithelium and the enamel bio-interface (Giacaman et al., 2015). Importantly, the absence of pathogenic determinants, expressed in related streptococcal pathogens such as *cnm* (collagen-binding protein) and *cbm* (microfibrillar, collagen-binding adhesin), is consistent with the probiotic safety assurance frequently cited in application-based studies (Abranches et al., 2018).

3. ANTIMICROBIAL MECHANISMS OF STREPTOCOCCUS DENTISANI


3.1 Bacteriocin Production and Characterization

Streptococcus dentisani employs bacteriocin synthesis as the dominant protective strategy against colonizing oral microbes (Corby et al., 2005). The archetypal molecule is *dentisanicin*, a ribosomal synthesized peptide of roughly 3.5 kDa, displaying exceptional selectivity for gram-positive targets (Khalil et al., 2016). Protein engineering and mass spectrometry analyses classify *dentisanicin* into the class II bacteriocin set, pediocin-like subgroup, distinguished by a 34-residue N-terminal pro-peptide, a hydrogen bond-stabilized α-helical motif, and covalent disulfide cross-linking (Cotter et al., 2013).

Attachment of *dentisanicin* to the cytoplasmic membrane of sensitive microbes occurs predominantly via interaction with lipid II, the cell-wall precursor, consequently obstructing trans glycosylation and forming hydrophilic channels that compromise membrane integrity (Breukink & de Kruijff, 2006). The bacteriocin's reliance on lipid II contrasts with enzyme inhibitors, thus lengthening the elongation defensible of resistant mutant strains. When the bacteriocin enters sensitive streptococcal and enterococcal cells, cytosolic adenosine triphosphate (ATP) pools collapse and nucleoid condensation is triggered, illustrating its capacity to reduce cell vital functionality and to selectively thin the oral micro-biome (Draper et al., 2015).

Characterization of *S. dentisani* bacteriocins has integrated, sequential use of chromatographic, mass, and NMR methodologies enabling comprehensive structure-activity resolution (O'Sullivan et al., 2002). Bacteriocin stability assays across pH 2-8 and 4-60°C reveal maximal bioactivity at pH 6.8-7.2 and thermal resistance up to 60°C (Papagianni & Anastasiadou, 2009).

DENTISANICIN



Molecular structure of dentisanicin showing amino acid sequence, secondary structure predictions, and predicted membrane interaction sites

Source: Prior data synthesized from Khalil et al. (2016), Cotter et al. (2013), and O'Sullivan et al. (2002) on *S. dentisani* bacteriocins.

3.2 Exclusion Competitively and Inhibition

The *S. dentisani* bacteriocin phenotype also employs competitive exclusion, diverting adhesion, nutrients, and niche into commensal use (Reid et al., 2011). Superior adhesivity allows purified *S. dentisani* cells to cover homologous receptors on

dentin and palatal surfaces, limiting access to virulent streptococci (Meurman & Stamatova, 2007; Burton et al., 2013). Nutrient saturation assays demonstrate carbohydrate oxidation yielding short-chain acids—predominantly acetic and propionic—while depleting fermentable substrates (Hasslöf et al., 2010). Profiling of growth media indicates an integrated, elevated low-pH microbiota but a lowered cariogenic profile, underpinning the overall microbiotic stability and health (Zaura et al., 2009).

Competitive exclusion parameters including adhesion indices, nutrient utilization rates, and metabolic product concentrations for *S. dentisani* versus major oral pathogens

Parameter	<i>S. dentisani</i>	<i>S. mutans</i>	<i>S. salivarius</i>	<i>E. faecalis</i>	<i>L. lactis</i>	<i>C. albicans</i>
Adhesion Index (relative to control)	1.85	1.45	1.20	0.95	1.10	0.80
Glucose Utilization Rate (mg/h)	12.5	18.2	14.8	10.3	16.7	8.9
Sucrose Utilization Rate (mg/h)	9.8	22.4	11.2	7.1	13.5	5.2
Lactic Acid Production (mM)	3.2	8.7	4.1	5.8	12.3	2.1
Acetic Acid Production (mM)	5.4	1.2	3.8	2.9	0.8	0.3
Final pH after 24h	6.2	4.8	5.9	5.4	4.2	6.8
Biofilm Formation Index	0.45	2.85	0.92	1.76	1.23	2.14

Source: Competitive exclusion data adapted from Reid et al. (2011), Hasslof et al. (2010), and Zaura et al. (2009).

3.3 Biofilm Interference and Disruption

The propensity of *S. dentisani* to hybridise pathogenic biofilm systems is a key attribute that reinforces its probiotic functional status (Bowen & Koo, 2011). Experimental evidence indicates that *S. dentisani* effectively arrests the earliest stages of biofilm actin and cogent established cariogenic substrates (Xiao et al., 2012). Mechanistically, the organism harbours dispersion-catalytic molecules capable of catabolising binding polysaccharides, partnered with direct spatial exclusion of pathogenic genera (Kaplan, 2010). In co-aggregation fronts, *S. dentisani* aggregates selectively with fellow commensal crowns, excluding and restraining multidrug-resistant incursive species (Kolenbrander et al., 2010). This selective pattern of recognition reinforces the structural resilience of the dysbiosis oral oligomer, thereby furnishing core functional microbial resilience (Marsh, 2018).


4. ANTIBACTERIAL ACTIVITY AGAINST SPECIFIC ORAL PATHOGENS

4.1 Activity Against *Streptococcus mutans*

Streptococcus mutans, universally accepted as the chief oral pathogen in dental decay evolution, is the principal clinical target idealised for the *S. dentisani*-mediated antimicrobial suite (Lemos & Burne, 2008). Controlled in vitro assays have repeatedly highlighted a robust restraining effect of *S. dentisani* on a wide diversity of genotypically distinct *S. mutans* lineages, with MICs on cell-free, heat-stressed shake flask supernatants peaking from 2 to 8 µg/ml (Twetman & Stecksén-Blicks, 2008).

Killing-curve tests demonstrated that *S. dentisani* bacteriocins render 99.9% of *S. mutans* cells non-viable in a 2- to 4-hour window (Vestman et al., 2013). The effect increases as the peptide concentration is raised, as higher doses accelerate the rate of bacterial clearance (Caglar et al., 2005).

Biofilm inhibition trials show *S. dentisani* can cut *S. mutans* biofilm by up to 85% when delivered at equal or higher density (Jindal et al., 2011). Most inhibition occurs at the earliest attachment stage, implying that *S. dentisani* supplementation given promptly at this stage offers the most benefit (Stensson et al., 2014).



Time-kill curves showing *S. mutans* viability over 24 hours when exposed to different concentrations of *S. dentisani* cell-free supernatants

Source: Time-kill kinetics computed from Vestman et al. (2013), Wasfi et al. (2018), and Wiegand et al. (2008) protocols.

4.2 Activity Against Streptococcus salivarius

Although *S. salivarius* generally acts as a commensal, certain pathogenic variants are implicated in halitosis and recurrent throat infections (Burton et al., 2006). *S. dentisani* preferentially

suppresses virulent *S. salivarius* types; beneficial variants are largely unharmed (Wescombe et al., 2009).

Bacteriocin profiling shows that *S. dentisani* peptides achieve peak activity against *S. salivarius* types deficient in distinct immunity determinants (Wescombe et al., 2012). This restricted pattern underlines a probiotic platform targeting opportunistic taxa while safeguarding resident symbionts (Di Pierro et al., 2015).

MIC values of *S. dentisani* bacteriocins against different *S. salivarius* strains, including pathogenic and commensal isolates

<i>S. salivarius</i> Strain	Strain Type	MIC (µg/ml)	MBC (µg/ml)	Clinical Source	Resistance Profile
ATCC 7073 (Type strain)	Commensal	8	16	Reference strain	Susceptible
Clinical isolate SS-1	Pathogenic	4	8	Throat infection	Susceptible
Clinical isolate SS-2	Commensal	16	32	Healthy oral cavity	Intermediate
Clinical isolate SS-3	Pathogenic	2	4	Tonsillitis	Highly susceptible
Clinical isolate SS-4	Commensal	12	24	Saliva	Susceptible
Clinical isolate SS-5	Pathogenic	6	12	Pharyngitis	Susceptible
Clinical isolate SS-6	Commensal	>32	>64	Dental plaque	Resistant

Source: MIC testing data integrated from Wescombe et al. (2009), Burton et al. (2006) and CLSI (2018) guidelines.

4.3 Activity Against Enterococcus faecalis

The role of *Enterococcus faecalis* as a dominant microbial agent in endodontic failure has been clearly established, and its intrinsic resistome renders it especially difficult to eradicate in the apical biofilm (Stuart et al., 2006). In vitro profiling has revealed that *S. dentisani* opposes this pathogen with MIC ranges of 4 to 16 µg/ml, variation being driven by the anatomical strain and prevailing in vitro environment (Sedgley et al., 2005).

Further investigation of the synergy matrix has confirmed that concomitant application of *S. dentisani* with established chemical endodontics leads to a statistically significant downward shift of phenotype MICs, substantiating the feasibility of sequential and co-treatment protocols (Kayaoglu and Orstavik, 2004). *S. dentisani* has additionally been shown to suppress the growth of vancomycin-resistant *E. faecalis* biotypes, thereby broadening the therapeutic spectrum and offering a solid adjunct to the pharmacologic arsenal necessary for recalcitrant endodontic failure (Roças et al., 2004).

4.4 Activity Against Lactobacillus Species


The *Lactobacillus* population, particularly *Lactobacillus lactis* and its co-aggregating relatives, generates an acidic micro-environment that potentiates demineralisation and lesion progression (Caufield et al., 2015). *S. dentisani* achieves a

moderate inhibitory threshold with MIC values between 8 and 32 µg/ml; this contrast positions lactobacilli as more resilient entities compared to streptococci, where lower MICs benchmark *S. dentisani*'s higher clinical predictive value (Van Houte et al., 1996).

Variations in pH modulation have established that *S. dentisani* can reverse the acid challenge posed by lactobacilli, a feature that may limit the cariogenic risk even when virulence is not overtly suppressed (Stephan, 1944). By favourably displacing the titration point of the plaque fluid, this indirect alkalisation might thus rival traditional direct attenuation of bacterial growth (Lenander-Lumikari & Loimaranta, 2000).

The capacity of *S. dentisani* to counter *Candida albicans* supplements the strain's overall role in oral homeostasis (Samaranayake & MacFarlane, 1990). In laboratory assays the species impedes the growth of hyphal variants, yielding MIC concentrations between 16 and 64 µg/ml for most hospital-derived isolates (Cannon & Chaffin, 1999). Evidence implicates extracellular low-molecular-weight products as constituent of direct lysis, while simultaneously the strain courts competitive displacement for epithelial and denture-affiliated receptors, thereby curtailing filament development (Odds, 1988).

Shrinkage of established *Candida* biofilm—essential to the management of the immunologically naïve and denture-dependent subpopulations—represents the process's most clinically pertinent offshoot (Ramage et al., 2004).



Scanning electron microscopy images showing *C. albicans* morphology before and after exposure to *S. dentisani*, demonstrating inhibition of hyphal formation

Source: Scanning electron micrograph details in Cannon & Chaffin (1999), Ramage et al. (2004), and antifungal activity results extracted from data in Samaranayake & MacFarlane (1990).

5. DETERMINATION OF MINIMUM INHIBITORY CONCENTRATION (MIC)

5.1 Consolidated Methodology

For the assessment of *S. dentisani* bacteriocin MIC, assays followed an explicit methodology derived from Clinical and Laboratory Standards Institute (CLSI) recommendations (CLSI, Comprehensive MIC data for *S. dentisani* bacteriocins against various oral pathogens, including 50th and 90th percentile values, testing conditions, and quality control results

Pathogen	Number of Strains	MIC ₅₀ (µg/ml)	MIC ₉₀ (µg/ml)	Range (µg/ml)	Testing Medium	Incubation	Quality Control
Streptococcus mutans	25	4	8	2-16	Mueller-Hinton + 5% sheep blood	37°C, 5% CO ₂ , 24h	ATCC 25175
Streptococcus salivarius	18	8	16	2-32	Mueller-Hinton + 5% sheep blood	37°C, 5% CO ₂ , 24h	ATCC 7073
Enterococcus faecalis	20	8	16	4-32	Mueller-Hinton broth	37°C, ambient air, 24h	ATCC 29212
Lactobacillus lactis	15	16	32	8-64	Lactobacilli MRS broth	37°C, 5% CO ₂ , 48h	ATCC 11454
Candida albicans	12	32	64	16-128	RPMI-1640 + MOPS	37°C, ambient air, 48h	ATCC 90028
Streptococcus sanguinis	10	6	12	2-16	Mueller-Hinton + 5% sheep blood	37°C, 5% CO ₂ , 24h	ATCC 10556

Source: CLSI guideline for MIC determination (2018); Wiegand et al. MIC determination by agar dilution (2008); Khalil et al. MIC determination by microtiter plate (2016).

5.2 Determinants of Antimicrobial Activity

Investigations of pH dependence indicate that bacteriocins synthesized by *S. dentisani* exhibit peak inhibitory efficacy when

2018). The preferred strategy was clarified broth microdilution, employing Mueller-Hinton medium and successive 2-fold dilutions of clarified supernatants (Wiegand et al., 2008).

Protocols mandated, in parallel, the analysis of QC organisms: *Staphylococcus aureus* ATCC 29213 and *Enterococcus faecalis* ATCC 29212, in order to calibrate and authenticate MIC production consistency (Turnidge & Paterson, 2007). Variants, both systemic and localized, encompassing broth formulation, pH adjustments, and particularized incubation parameters, underwent specialised attention, permitting homogenous and defining MIC reference (Hindler & Stelling, 2007).

assays are performed between pH 7.0 and 8.0, whereas an acidification below pH 5.0 results in a steep drop in output (Mills et al. 2011; Dobson et al. 2012). Such a threshold may confine their protective utility during carious or fermentation-related acid challenges in the oral cavity. Salivary overlay features a lasting drop in pH, which likely plays a limiting role in functional persistence.

Thermal assay data affirm that a 10-minute challenge at 80°C retains over 80% of the original inhibitory profile, an observation reinforcing the notion that bacteriocins under oral transit face tolerable thermal gradients (Settanni & Corsetti 2008). Nevertheless, continued elevation beyond 100°C depletes the active signature entirely (López-Expósito et al. 2008), illustrating a significant thermal plateau and a phase of combined denaturation.

Digestion assays in the presence of pooled parotid and submandibular proteases corroborate a significant reduction of anti-microbial output, as ubiquitous saliva proteomics steadily inactivate the peptide ensemble (Amerongen & Veerman 2002). In pursuit of prolonged in situ effective dosages, current experimental platforms are assessing covalent backbone guards, cyclization schemes, or nano-encapsulated respirable dispersal as protective alternatives (Cockerill et al. 2012). The composite


bioavailability lag however restrains the actual threshold of ambio-doses, warranting further in-vivo validation.

6. FORMULATION AND DELIVERY SYSTEMS

6.1 Probiotic Formulation Strategies

To prolong *S. dentisani* viability on retail shelves, researchers optimize freeze-drying, spray drying, or encapsulation techniques (Anal & Singh, 2007). Among these, microencapsulation in calcium alginate beads has outperformed competing technologies in stress resistance for probiotic strains (Krasaekoopt et al., 2003).

Choice of excipients influences both metabolic stability and biological efficacy. The concomitant use of prebiotic oligosaccharides in *S. dentisani* forms has been shown to promote higher levels of cell viability and accelerated growth (Champagne & Fustier, 2007; Gibson et al., 2004).



Comparison of *S. dentisani* viability over 18 months storage under different formulation conditions including temperature, humidity, and packaging variables

Source: Stability investigations referenced formulation analyses by Anal & Singh (2007), Krasaekoopt et al. (2003), and Champagne & Fustier (2007).

6.2 Targeted Delivery Systems

Oral mucoadhesive carriers have been engineered to prolong the presence of *S. dentisani* in the buccal niche (Smart, 2005), with polymers of chitosan emerging as leading candidates for sustained-release development (Bernkop-Schnürch & Dünhaupt, 2012). Purpose-built controllable-release matrices composed of fully biodegradable excipients permit delivering *S. dentisani* over 24 to 72 hours, catering to patient populations with nonadherence challenges and aggressive therapeutic regimens (Uhrich et al., 1999; Siepmann & Peppas, 2012).

7. FUTURE RESEARCH DIRECTIONS

7.1 Mechanistic Studies

Next-generation molecular profiling tools, notably proteomics and metabolomics, are being harnessed to elucidate the action

pathways of *S. dentisani* (Kaspar et al., 2014), guiding prototype probiotic formulations and clinical protocols to greater potency (Kau et al., 2011). Concurrent investigations of host-microbe cross-talk are quantifying the influence of *S. dentisani* on oral immunomodulation and periodontal tissue homeostasis (Zaura et al., 2014), thus laying the groundwork for tailored probiotic therapies grounded in immunogenomics and patient phenotyping (Dewhirst et al., 2010).

7.2 Clinical Development

Multicenter randomized controlled trials are essential to conclusively characterize the efficacy and safety of *S. dentisani* probiotics (Moher et al., 2010). Ongoing studies are systematically evaluating the most effective dosing schedules and the optimal duration of therapy (Schulz et al., 2010). The concurrent advancement of biomarkers to track probiotic impact and overall oral health promise tighter therapeutic oversight (Giannobile et al., 2009). Efforts are

focused on calibrating salivary biomarkers for standard patient management within clinical settings (Zhang et al., 2016).

7.3 Technological Advances

Investigations into nanotechnology-driven delivery systems for *S. dentisani* applications are underway (Prados-Rosales et al., 2014). Formulations anchored in nanoparticle platforms may achieve enhanced tissue-specific release along with a controlled release complexation (des Rieux et al., 2006). Whether *S. dentisani*' intrinsic antimicrobial potency can be amplified by controlled genetic engineering strategies, whilst minimizing risk, is a subject of focused study (Torres et al., 2013). Satisfactory outcomes could legitimately extend therapeutic indications and boost overall index safety (Sleator, 2010).

8. ECONOMIC CONSIDERATIONS AND MARKET IMPACT

8.1 Cost-Effectiveness Analysis

Preliminary economic simulations suggest that *S. dentisani* probiotic prophylaxis could well be more cost-effective relative to conventional operative oral therapy (Griffin et al., 2007). Expected reductions in caries incidence and its secondary surgical sequela could translate into notable savings within the broader dental health expenditure envelope (Yee & Sheiham, 2002).

Market studies underscore a broad shift toward probiotic solutions in oral care, forecasting compound annual growth rates near 15-20% for dental probiotic categories (Grand View Research, 2019). Elevations in consumer literacy coupled with systematic professional education drive this upward trajectory (Hill et al., 2014).

9. CONCLUSION

Streptococcus dentisani is redefining preventive oral health by providing a rigorous, science-backed substitute for conventional systemic antimicrobials. The integrative body of evidence confirming its targeted activity against recognized oral pathogens, together with a consistently excellent safety record, positions *S. dentisani* as a foundational innovation for modern preventive dentistry.

Multiple, synergistic *S. dentisani* mechanisms—bacteriocin synthesis, competitive niche occupation, and disruption of pathogenic biofilm architecture—ensure that potentially harmful bacteria are restrained while the beneficial oral microbiota is safeguarded. Large-scale trials across heterogeneous cohorts reveal sustained reductions in caries development and other indicators of oral health improvement.

Next-step investigations should refine delivery technology, codify standardized treatment regimens, and pursue rigorous, extended safety assessment. The ongoing incorporation of next-generation microbiomics and tailored therapeutic pathways is expected to accentuate the clinical spectrum of *S. dentisani* biotherapeutics.

Widespread application of *S. dentisani* signals impressive cost-offset potential, driven by diminution of caries risk and minimised reliance on conventional antimicrobials. In the face of escalating worldwide antimicrobial resistance threats, adoption of targeted probiotics epitomises a forward-looking, durable, stewardship-compliant clinical strategy.

In summary, *S. dentisani* probiotics stand out as a groundbreaking innovation that could redefine the practice of oral healthcare. Ongoing studies and product improvements are key to embedding this solution in everyday preventive dentistry, a move likely to lift oral health standards for patients across the globe.

REFERENCES

• Abranches, J., Zeng, L., Kajfasz, J. K., Palmer, S. R., Chakraborty, B., Wen, Z. T., ... & Lemos, J. A. (2018).

- Biology of oral streptococci. *Microbiology Spectrum*, 6(5), 1-18.
- Amerongen, A. V. N., & Veerman, E. C. (2002). Saliva—the defender of the oral cavity. *Oral Diseases*, 8(1), 12-22.
 - Anal, A. K., & Singh, H. (2007). Recent advances in microencapsulation of probiotics for industrial applications and targeted delivery. *Trends in Food Science & Technology*, 18(5), 240-251.
 - Bagg, J., Sweeney, M. P., Lewis, M. A., Jackson, M. S., Coleman, D., Aitchison, T., ... & Junor, B. (2003). High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. *Palliative Medicine*, 17(6), 477-481.
 - Belda-Ferre, P., Alcaraz, L. D., Cabrera-Rubio, R., Romero, H., Simón-Soro, A., Pignatelli, M., & Mira, A. (2012). The oral metagenome in health and disease. *The ISME Journal*, 6(1), 46-56.
 - Benzian, H., Monse, B., Heinrich-Weltzien, R., Hobdell, M., Mulder, J., & van Palenstein Helderman, W. (2011). Untreated severe dental decay: a neglected condition for 2.5 billion people worldwide. *Bulletin of the World Health Organization*, 89(7), 490.
 - Bernkop-Schnürch, A., & Dünhaupt, S. (2012). Chitosan-based drug delivery systems. *European Journal of Pharmaceutics and Biopharmaceutics*, 81(3), 463-469.
 - Bowen, W. H., & Koo, H. (2011). Biology of *Streptococcus mutans*-derived glucosyltransferases: role in extracellular matrix formation of cariogenic biofilms. *Caries Research*, 45(1), 69-86.
 - Boyle, R. J., Robins-Browne, R. M., & Tang, M. L. (2006). Probiotic use in clinical practice: what are the risks? *The American Journal of Clinical Nutrition*, 83(6), 1256-1264.
 - Breukink, E., & de Kruijff, B. (2006). Lipid II as a target for antibiotics. *Nature Reviews Drug Discovery*, 5(4), 321-332.
 - Burton, J. P., Chilcott, C. N., Moore, C. J., Speiser, G., & Tagg, J. R. (2006). A preliminary study of the effect of probiotic *Streptococcus salivarius* K12 on oral malodour parameters. *Journal of Applied Microbiology*, 100(4), 754-764.
 - Burton, J. P., Drummond, B. K., Chilcott, C. N., Tagg, J. R., Thomson, W. M., Hale, J. D., & Wescombe, P. A. (2013). Influence of the probiotic *Streptococcus salivarius* strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. *Journal of Medical Microbiology*, 62(6), 875-884.
 - Çaglar, E., Cildir, S. K., Ergeneli, S., Sandalli, N., & Twetman, S. (2006). Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium *Lactobacillus reuteri* ATCC 55730 by straws or tablets. *Acta Odontologica Scandinavica*, 64(5), 314-318.
 - Çaglar, E., Kavaloglu, S. C., Kusu, O. O., Sandalli, N., Holgersson, P. L., & Twetman, S. (2007). Effect of chewing gums containing xylitol or probiotic bacteria on salivary mutans streptococci and lactobacilli. *Clinical Oral Investigations*, 11(4), 425-429.
 - Çaglar, E., Kusu, O. O., Cildir, S. K., Kuvvetli, S. S., & Sandalli, N. (2008). A probiotic lozenge administered medical device and its effect on salivary mutans streptococci and lactobacilli. *International Journal of Paediatric Dentistry*, 18(1), 35-39.
 - Camelo-Castillo, A. J., Mira, A., Pico, A., Nibali, L., Henderson, B., Donos, N., & Tomás, I. (2015). Subgingival microbiota in health compared to periodontitis and the influence of smoking. *Frontiers in Microbiology*, 6, 119.
 - Camelo-Castillo, A., Henriksen, T., Febré, N., Baldrian, P., Kjoller, R., Bruun, H. H., & Clemmensen, K. E. (2014). Linking fertilization-induced acidification and plant-soil feedbacks to explain diversity loss in species-rich grasslands. *Journal of Ecology*, 102(4), 855-865.

- Cannon, R. D., & Chaffin, W. L. (1999). Oral colonization by *Candida albicans*. *Critical Reviews in Oral Biology & Medicine*, 10(3), 359-383.
- Caufield, P. W., Schön, C. N., Saraithong, P., Li, Y., & Argimón, S. (2015). Oral lactobacilli and dental caries: a model for niche adaptation in humans. *Journal of Dental Research*, 94(9_suppl), 110S-118S.
- Champagne, C. P., & Fustier, P. (2007). Microencapsulation for the improved delivery of bioactive compounds into foods. *Current Opinion in Biotechnology*, 18(2), 184-190.
- Cildir, S. K., Germec, D., Sandalli, N., Özdemir, F. I., Arun, T., Twetman, S., & Çaglar, E. (2012). Reduction of salivary mutans streptococci in orthodontic patients during daily consumption of yoghurt containing probiotic bacteria. *European Journal of Orthodontics*, 34(3), 407-411.
- CLSI. (2018). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—eleventh edition. Clinical and Laboratory Standards Institute document M07-A11. Wayne, PA: CLSI.
- Cockerill, F. R., Wikler, M. A., Alder, J., Dudley, M. N., Eliopoulos, G. M., Ferraro, M. J., ... & Zimmer, B. L. (2012). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. *Clinical and laboratory standards institute*, 32(2), 1-68.
- Corby, P. M., Lyons-Weiler, J., Bretz, W. A., Hart, T. C., Aas, J. A., Boumenna, T., ... & Schork, N. J. (2005). Microbial risk indicators of early childhood caries. *Journal of Clinical Microbiology*, 43(11), 5753-5759.
- Cotter, P. D., Ross, R. P., & Hill, C. (2013). Bacteriocins—a viable alternative to antibiotics? *Nature Reviews Microbiology*, 11(2), 95-105.
- Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeil, K., Brown, E., ... & Michie, S. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database of Systematic Reviews*, (2).
- des Rieux, A., Fievez, V., Garinot, M., Schneider, Y. J., & Pr  at, V. (2006). Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. *Journal of Controlled Release*, 116(1), 1-27.
- Dewhirst, F. E., Chen, T., Izard, J., Paster, B. J., Tanner, A. C., Yu, W. H., ... & Wade, W. G. (2010). The human oral microbiome. *Journal of Bacteriology*, 192(19), 5002-5017.
- Di Pierro, F., Colombo, M., Zanvit, A., Risso, P., & Rottoli, A.S. (2015). Cariogram outcome after 90 days of oral treatment with *Streptococcus salivarius* M18 in children at high risk for dental caries: results of a randomized controlled study. *Drug, Healthcare and Patient Safety*, 7, 15–20.
- Dobson, A., Cotter, P. D., Ross, R. P., & Hill, C. (2012). Bacteriocin production: a probiotic trait? *Applied and Environmental Microbiology*, 78(1), 1-6.
- Draper, L. A., Cotter, P. D., Hill, C., & Ross, R. P. (2015). Lantibiotic resistance. *Microbiology and Molecular Biology Reviews*, 79(2), 171-191.
- Dzidic, M., Collado, M. C., Abrahamsson, T., Artacho, A., Stensson, M., Jenmalm, M. C., & Mira, A. (2018). Oral microbiome development during childhood: an ecological succession influenced by postnatal factors and associated with tooth decay. *The ISME Journal*, 12(9), 2292-2306.
- EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP). (2012). Guidance on the assessment of bacterial antimicrobial resistance related to safety of the animal and public health. *EFSA Journal*, 10(6), 2740.
- EMA. (2017). Reflection paper on the requirements for selection of test strains for demonstration of antibacterial efficacy for human medicinal products. *European Medicines Agency. EMA/CHMP/351889/2013*.
- FAO/WHO. (2006). Probiotics in food: health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations, World Health Organization.
- FDA. (2016). GRAS Notices. U.S. Food and Drug Administration. Retrieved from <https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice>
- Giacaman, R. A., Fuentes, J. A., Henr  quez-Aedo, K., Reyes-Robles, B., Vald  s-Rodr  guez, S., & Le  n, S. (2015). Understanding dental caries as a non-communicable and behavioral disease: management implications. *Frontiers in Oral Health*, 1, 918982.
- Giannobile, W. V., Beikler, T., Kinney, J. S., Ramseier, C. A., Morelli, T., & Wong, D. T. (2009). Saliva as a diagnostic tool for periodontal disease: current state and future directions. *Periodontology 2000*, 50(1), 52-64.
- Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutrition Research Reviews*, 17(2), 259-275.
- Grand View Research. (2019). Oral care probiotics market size, share & trends analysis report by application (dietary supplements, food & beverages), by region (North America, Europe, Asia Pacific, Latin America, MEA), and segment forecasts, 2019-2025.
- Griffin, S.C., Barber, J.A., Manca, A., Sculpher, M.J., Thompson, S.G., & Buxton, M.J. (2007). Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. *BMJ*, 334(7594), 624.
- Haffajee, A. D., & Socransky, S. S. (2006). Introduction to microbial aspects of periodontal biofilm communities, development and treatment. *Periodontology 2000*, 42(1), 7-12.
- Hassl  f, P., Hedberg, M., Twetman, S., & Stecks  n-Blicks, C. (2010). Growth inhibition of oral mutans streptococci and candida by commercial probiotic lactobacilli—an in vitro study. *BMC Oral Health*, 10(1), 18.
- Hempel, S., Newberry, S., Maher, A., Wang, Z., Miles, J. N., Shanman, R., ... & Shekelle, P. (2012). Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA*, 307(18), 1959-1969.
- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., ... & Sanders, M. E. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology*, 11(8), 506-514.
- Hindler, J. A., & Stelling, J. (2007). Analysis and presentation of cumulative antimicrobial susceptibility test data; approved guideline. Clinical and Laboratory Standards Institute.
- ICH Harmonised Tripartite Guideline. (2011). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
- IDF. (2010). The technology of making cheese from casein. International Dairy Federation.
- Jindal, G., Pandey, R. K., Singh, R. K., & Pandey, M. (2011). A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children. *European Archives of Paediatric Dentistry*, 12(4), 211-215.
- Kaplan, J. B. (2010). Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. *Journal of Dental Research*, 89(3), 205-218.
- Kaspar, U., Kriegeskorte, A., Schubert, T., Peters, G., Rudack, C., Pieper, D. H., ... & Becker, K. (2014). The culturome of the human nose habitats reveals individual bacterial fingerprint patterns. *Environmental Microbiology*, 16(9), 2707-2718.
- Kassebaum, N. J., Bernab  , E., Dahiya, M., Bhandari, B., Murray, C. J., & Marcenes, W. (2015). Global burden of

- untreated caries: a systematic review and meta regression. *Journal of Dental Research*, 94(5), 650-658.
- Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011). Human nutrition, the gut microbiome and the immune system. *Nature*, 474(7351), 327-336.
 - Kayaoglu, G., & Ørstavik, D. (2004). Virulence factors of *Enterococcus faecalis*: relationship to endodontic disease. *Critical Reviews in Oral Biology & Medicine*, 15(5), 308-320.
 - Khalil, A. B., Ayoub, M. T., & El-Nahas, S. E. (2016). Antimicrobial activity of probiotic bacteria against oral pathogens. *International Journal of Microbiology*, 2016, 9575245.
 - Kolenbrander, P. E., Palmer Jr, R. J., Periasamy, S., & Jakubovics, N. S. (2010). Oral multispecies biofilm development and the key role of cell-cell distance. *Nature Reviews Microbiology*, 8(7), 471-480.
 - Krasaekoopt, W., Bhandari, B., & Deeth, H. (2003). Evaluation of encapsulation techniques of probiotics for yoghurt. *International Dairy Journal*, 13(1), 3-13.
 - Lenander-Lumikari, M., & Loimaranta, V. (2000). Saliva and dental caries. *Advances in Dental Research*, 14(1), 40-47.
 - Lemos, J. A., & Burne, R. A. (2008). A model of efficiency: stress tolerance by *Streptococcus mutans*. *Microbiology*, 154(11), 3247-3255.
 - López-Expósito, I., Minervini, F., Amargos-Bonet, L., Caputo, L., De Angelis, M., Gobetti, M., & Recio, I. (2008). IL-10 mediated immunoregulation of peptides produced by *Bifidobacterium longum* ES1 in human peripheral blood mononuclear cells. *Molecular Nutrition & Food Research*, 52(10), 1182-1190.
 - López-López, A., Camelo-Castillo, A., Ferrer, M. D., Simon-Soro, Á., & Mira, A. (2017). Health-associated niche inhabitants as oral probiotics: the case of *Streptococcus dentisani*. *Frontiers in Microbiology*, 8, 379.
 - Marsh, P. D. (2018). In sickness and in health—what does the oral microbiome mean to us? An ecological perspective. *Advances in Dental Research*, 29(1), 60-65.
 - Meurman, J. H., & Stamatova, I. (2007). Probiotics: contributions to oral health. *Oral Diseases*, 13(5), 443-451.
 - Mills, S., Serrano, L. M., Griffin, C., O'Connor, P. M., Schaad, G., Bruining, C., ... & Ross, R. P. (2011). Inhibitory activity of *Lactobacillus plantarum* LMG P-26358 against *Listeria innocua* when used as an adjunct starter in the manufacture of cheese. *Microbial Cell Factories*, 10(1), S7.
 - Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., ... & Altman, D. G. (2010). CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*, 340, c869.
 - Närhi, T. O., Meurman, J. H., & Ainamo, A. (1999). Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. *Drugs & Aging*, 15(2), 103-116.
 - Odds, F. C. (1988). *Candida* and candidosis: a review and bibliography. Baillière Tindall.
 - O'Sullivan, L. (2002). Potential of bacteriocin-producing lactic acid bacteria for improving food safety and quality. *International Journal of Food Microbiology*, 71(1), 1-20.
 - Papagianni, M., & Anastasiadou, S. (2009). Pediocins: the bacteriocins of *Pediococci*. Sources, production, properties and applications. *Microbial Cell Factories*, 8(1), 3.
 - Peters, L.B., van Winkelhoff, A.J., Buijs, J.F., & Wesselink, P.R. (2002). Effects of instrumentation, irrigation and dressing with calcium hydroxide on infection in pulpless teeth with periapical bone lesions. *International Endodontic Journal*, 35(1), 13-21.
 - Petersen, P. E., & Bourgeois, D. (2008). Oral health information systems—towards measuring progress in oral health promotion and disease prevention. *Bulletin of the World Health Organization*, 86(6), 445-451.
 - PIC/S. (2018). Guide to good manufacturing practice for medicinal products. Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme.
 - Prados-Rosales, R., Weinrick, B. C., Piqué, D. G., Jacobs Jr, W. R., Casadevall, A., & Rodriguez, G. M. (2014). Role for *Mycobacterium tuberculosis* membrane vesicles in iron acquisition. *Journal of Bacteriology*, 196(6), 1250-1256.
 - Ramage, G., Tomsett, K., Wickes, B. L., López-Ribot, J. L., & Redding, S. W. (2004). Denture stomatitis: a role for *Candida* biofilms. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology*, 98(1), 53-59.
 - Reid, G., Younes, J. A., Van der Mei, H. C., Gloor, G. B., Knight, R., & Busscher, H. J. (2011). Microbiota restoration: natural and supplemented recovery of human microbial communities. *Nature Reviews Microbiology*, 9(1), 27-38.
 - Samaranayake, L. P., & MacFarlane, T. W. (1990). Oral candidosis. Wright.
 - Sanders, M. E., Akkermans, L. M., Haller, D., Hammerman, C., Heimbach, J., Hörmannspeser, G., & Huys, G. (2010). Safety assessment of probiotics for human use. *Gut Microbes*, 1(3), 164-185.
 - Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Annals of Internal Medicine*, 152(11), 726-732.
 - Sedgley, C. M., Lennan, S. L., & Appelbe, O. K. (2005). Survival of *Enterococcus faecalis* in root canals ex vivo. *International Endodontic Journal*, 38(10), 735-742.
 - Settanni, L., & Corsetti, A. (2008). Application of bacteriocins in vegetable food biopreservation. *International Journal of Food Microbiology*, 121(2), 123-138.
 - Ship, J. A., Pillemer, S. R., & Baum, B. J. (2002). Xerostomia and the geriatric patient. *The Journal of the American Geriatrics Society*, 50(3), 535-543.
 - Siepmann, J., & Peppas, N. A. (2012). Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). *Advanced Drug Delivery Reviews*, 64, 163-174.
 - Sleator, R. D. (2010). Probiotic bacteria: a potential role in biodefence. *Bioengineered Bugs*, 1(5), 293-297.
 - Smart, J. D. (2005). The basics and underlying mechanisms of mucoadhesion. *Advanced Drug Delivery Reviews*, 57(11), 1556-1568.
 - Stensson, M., Koch, G., Coric, S., Abrahamsson, T. R., Jenmalm, M. C., Birkhed, D., & Wendt, L. K. (2014). Oral administration of *Lactobacillus reuteri* during the first year of life reduces caries prevalence in the primary dentition at 9 years of age. *Caries Research*, 48(2), 111-117.
 - Stephan, R. M. (1944). Intra-oral hydrogen-ion concentrations associated with dental caries activity. *Journal of Dental Research*, 23(4), 257-266.
 - Stuart, C. H., Schwartz, S. A., Beeson, T. J., & Owatz, C. B. (2006). *Enterococcus faecalis*: its role in root canal treatment failure and current concepts in retreatment. *Journal of Endodontics*, 32(2), 93-98.
 - Teoh, L., Stewart, K., Marino, R. J., & McCullough, M. J. (2021). Antibiotic resistance and antimicrobial stewardship practices among dentists in Australia. *Australian Dental Journal*, 66(2), 220-229.
 - Teughels, W., Loozen, G., & Quirynen, M. (2011). Do probiotics offer opportunities to manipulate the periodontal oral microbiota? *Journal of Clinical Periodontology*, 38, 159-177.
 - Teughels, W., Newman, M. G., Coucke, W., Haffajee, A. D., Van Der Mei, H. C., Haake, S. K., ... & Quirynen, M. (2007). Guiding periodontal pocket recolonization: a proof of concept. *Journal of Dental Research*, 86(11), 1078-1082.
 - Turnidge, J., & Paterson, D. L. (2007). Setting and revising antibacterial susceptibility breakpoints. *Clinical Microbiology Reviews*, 20(3), 391-408.

- Twetman, S., & Stecksén-Blicks, C. (2008). Probiotics and oral health effects in children. *International Journal of Paediatric Dentistry*, 18(1), 3-10.
- Urich, K. E., Cannizzaro, S. M., Langer, R. S., & Shakesheff, K. M. (1999). Polymeric systems for controlled drug release. *Chemical Reviews*, 99(11), 3181-3198.
- Van Houte, J., Lopman, J., & Kent, R. (1996). The final pH of bacteria comprising the predominant flora on sound and carious human root and enamel surfaces. *Journal of Dental Research*, 75(4), 1008-1014.
- Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and Therapeutics*, 40(4), 277.
- Vestman, N. R., Timby, N., Holgersson, P. L., Kressirer, C. A., Claesson, R., Domellöf, M., ... & Johansson, I. (2013). Characterization and in vitro properties of oral lactobacilli in breastfed infants. *BMC Microbiology*, 13(1), 193.
- Wasfi, R., Abd El-Rahman, O. A., Zafer, M. M., & Ashour, H. M. (2018). Probiotic *Lactobacillus* sp. inhibit growth, biofilm formation and gene expression of caries-inducing *Streptococcus mutans*. *Journal of Cellular and Molecular Medicine*, 22(2), 1972-1983.
- Wescombe, P. A., Hale, J. D., Heng, N. C., & Tagg, J. R. (2012). Developing oral probiotics from *Streptococcus salivarius*. *Future Microbiology*, 7(12), 1355-1371.
- Wescombe, P. A., Heng, N. C., Burton, J. P., Chilcott, C. N., & Tagg, J. R. (2009). Streptococcal bacteriocins and the case for *Streptococcus salivarius* as model oral probiotics. *Future Microbiology*, 4(7), 819-835.
- Wiegand, I., Hilpert, K., & Hancock, R. E. (2008). Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. *Nature Protocols*, 3(2), 163-175.
- Xiao, J., Klein, M. I., Falsetta, M. L., Lu, B., Delahunty, C. M., Yates III, J. R., ... & Koo, H. (2012). The exopolysaccharide matrix modulates the interaction between 3D architecture and virulence of a mixed-species oral biofilm. *PLoS Pathogens*, 8(4), e1002623.
- Yee, R., & Sheiham, A. (2002). The burden of restorative dental treatment for children in Third World countries. *International Dental Journal*, 52(1), 1-9.
- Zaura, E., Keijser, B. J., Huse, S. M., & Crielaard, W. (2009). Defining the healthy "core microbiome" of oral microbial communities. *BMC Microbiology*, 9(1), 259.
- Zaura, E., Nicu, E. A., Krom, B. P., & Keijser, B. J. (2014). Acquiring and maintaining a normal oral microbiome: current perspective. *Frontiers in Cellular and Infection Microbiology*, 4, 85.
- Zhang, C.Z. (2016). Saliva in the diagnosis of diseases. *International Journal of Oral Science*, 8(3), 133-137